Company

Gemin X

As of the edition of 20 October 2026, Gemin X runs 2 drugs; it is on route A at 7 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

Gemin X was acquired.

  • Gemin X: acquired

Drugs by status

StatusCount
Stopped2
Total2

Where it needs a new molecule

Route A at 7 targets, route B at 0 targets.

Three of its 7 rows, by target and route
TargetRoute
BCL2L1 Bcl-2-like protein 1Route A
MCL1 Induced myeloid leukemia cell differentiation protein Mcl-1Route A
BCL2A1 Bcl-2-related protein A1Route A

All 7 rows on route A or B

In the product

7 company-target rows on route A or B; 4 are not shown here, and no score is.

Where its trials are

  • Cancer: 10 trials led
  • Blood and lymph: 9 trials led
  • Immune system: 5 trials led